Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O95721

UPID:
SNP29_HUMAN

ALTERNATIVE NAMES:
Soluble 29 kDa NSF attachment protein; Vesicle-membrane fusion protein SNAP-29

ALTERNATIVE UPACC:
O95721

BACKGROUND:
The Synaptosomal-associated protein 29, known as SNAP-29, is essential for the fusion of cellular membranes, playing a key role in autophagy and ciliogenesis. This protein's ability to form trans-SNARE complexes is crucial for membrane fusion processes, directly impacting autophagosome and lysosome fusion as well as membrane fusions necessary for ciliogenesis.

THERAPEUTIC SIGNIFICANCE:
Given SNAP-29's critical role in the pathogenesis of cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome, targeting this protein could offer novel therapeutic avenues. The exploration of SNAP-29's functions offers promising potential for developing targeted treatments for this complex syndrome.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.